Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation

Gerald V. Naccarelli, Deborah L. Wolbrette, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Robert Stevenson, Mario D. Gonzalez

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Background: This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant hydrochloride (RSD-1235), a novel antiarrhythmic drug that has relative atrial selectivity by blocking potassium channels that are present in the atria and not the ventricle. in addition, this drug has important rate-dependent sodium channel blocking properties. Methods: Currently, there few commercially approved intravenous antiarrhythmic agents for the conversion of atrial fibrillation. intravenously, vernakalant has been demonstrated to be useful in terminating over 50% of recent-onset atrial fibrillation (< 7 days duration) with minimal ventricular proarrhythmic effects. Intravenous vernakalant is not effective in terminating atrial flutter. Oral vernakalant is currently undergoing study and appeats to be effective in suppressing atrial fibrillation recurrences after cardioversion of persistent atrial fibrillation. Results/conclusion: Intravenous vernakalant has the potential to be an important agent in the conversion of atrial fibrillation and oral vernakalant may be a useful drug for the suppression of atrial fibrillation recurrences.

Original languageEnglish (US)
Pages (from-to)805-810
Number of pages6
JournalExpert Opinion on Investigational Drugs
Issue number5
StatePublished - May 1 2008

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation'. Together they form a unique fingerprint.

Cite this